Emergent Biosolutions Inc (EBS): How Hedge Funds Are Trading This Biotech Stock

As industrywide interest jumped, some big names have been driving this bullishness. Millennium Management, managed by Israel Englander, established the most outsized position in Emergent Biosolutions Inc (NYSE:EBS). Millennium Management had $2.4 million invested in the company at the end of the quarter. Matthew Tewksbury’s Stevens Capital Management also initiated a $0.5 million position during the quarter. The only other fund with a brand new Emergent Biosolutions Inc position is Peter Muller’s PDT Partners.

Let’s now take a look at hedge fund activity in other stocks – not necessarily in the same industry as Emergent Biosolutions Inc (NYSE:EBS) but similarly valued. These stocks are Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Sykes Enterprises, Incorporated (NASDAQ:SYKE), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), and Beneficial Bancorp Inc (NASDAQ:BNCL). All of these stocks’ market caps resemble Emergent Biosolutions Inc’s market cap.

As you can see these stocks had an average of 21.5 hedge funds with bullish positions and the average amount invested in these stocks was $151 million. That figure was $155 million in Emergent Biosolutions Inc’s case. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is the most popular stock in this table. On the other hand Sykes Enterprises, Incorporated (NASDAQ:SYKE) is the least popular one with only 16 bullish hedge fund positions. Emergent Biosolutions Inc (NYSE:EBS) is not the least popular stock in this group but hedge fund interest is still below average. This is a slightly negative signal and we’d rather spend our time researching stocks that hedge funds are piling on. In this regard Ariad Pharmaceuticals might be a better candidate to consider a long position in.